



RANZCO

The Royal Australian
and New Zealand
College of Ophthalmologists

Commercial projects - Clinical and Experimental Ophthalmology

Approved by: Board Version: Current Department: Member Support	Next review date: July 2025 Approval date: July 2022 Policy inventory number: 163.2022.07 08
---	---

1. Introduction

1.1. Purpose

This policy sets out the parameters of commercial opportunities and projects for *Clinical and Experimental Ophthalmology* and the approval pathway for them.

1.2. Who is it prepared for?

This policy applies to *Clinical and Experimental Ophthalmology*:

- Editor-in-Chief (EIC)
- Editor
- Editorial Board
- The publisher, Wiley Blackwell

1.3. Scope

This policy covers all commercial opportunities and projects with the editorial content of *Clinical and Experimental Ophthalmology*. It does not include general advertising within *Clinical and Experimental Ophthalmology*.

2. Strategic Alignment

This policy aligns with RANZCO's strategic aims of promoting ophthalmic education and research.

3. Background and issues

From time to time, the publisher has requested approval to include commercial opportunities and projects within the editorial content of *Clinical and Experimental Ophthalmology*. Understanding the review and approval pathway for these requests is important for upholding the integrity of *Clinical and Experimental Ophthalmology* and for managing commercial relationships and expectations.

4. Objectives

The objective of this policy is to provide clarity around the review and approval of commercial opportunities and projects within the editorial content of *Clinical and Experimental Ophthalmology*.

5. Policies

The publisher may at any time present commercial opportunities to the EIC of *Clinical and Experimental Ophthalmology* for consideration.

All commercial projects (including, but not limited to, print display advertising, educational sponsorships, company-sponsored content and online advertising) must be reviewed and approved by the EIC, on behalf of the *Clinical and Experimental Ophthalmology* Editorial Board, prior to implementation.

The EIC may not approve any commercial project which undermines the integrity of the peer reviewed manuscript within *Clinical and Experimental Ophthalmology*, the reputation of the *Clinical and Experimental Ophthalmology* journal, or the reputation of the College.

The *Clinical and Experimental Ophthalmology* Editorial Board and RANZCO Board support this position.

The publisher must respect the right of the EIC to decline any commercial venture proposed by the publisher, at any stage of development.

6. Monitoring and Evaluation

The success of this policy will be determined based on feedback from the EIC, which will be sought annually as part of the Committee Reporting cycle.

7. Record of amendments to this document

Page	Details of amendment	Date approved
All	New Policy	July 2022